BioXpress Therapeutics · Switzerland
BioXpress Therapeutics —
a premium provider of biosimilars.
Our mission is to ensure every patient around the world has access to affordable, highest-quality antibody biosimilar therapeutics. We achieve this by combining unique technical and industrial experience with cost-efficient manufacturing of these highly efficacious therapeutics.
About BioXpress
One focused team.
Unique industrial experience.
Founded in 2008, BioXpress is a Contract Research Organization (CRO) that combines expertise in cell-line development, analytical characterisation, process development, manufacturing and regulatory affairs to support complex biosimilar programmes.
- Monthey
- Switzerland
- 2008
- Founded
- Biosimilars
- Focus on mAbs
The BioXpress approach
One development.
Five connected disciplines.
Scientific, technical and regulatory decisions remain connected throughout a biosimilar development programme.
-
01
Cell-line
development -
02
Analytical
characterisation -
03
Process
development - 04 Manufacturing
-
05
Clinical & regulatory
development
Pipeline
A portfolio focused on
biosimilar mAbs.
Nine antibody biosimilar programmes form the BioXpress portfolio.
BXT 2318
Trastuzumab
HER2+ breast cancer · Gastric cancer
BXT 1523
Alemtuzumab
Multiple sclerosis · Haematological malignancies
BXT 2316
Bevacizumab
Multiple oncology indications · Anti-VEGF
BXT 2922
Adalimumab
Rheumatoid arthritis · Immune-mediated inflammatory diseases
BXT 2336
Rituximab
B-cell malignancies · Autoimmune diseases
BXT 2303
Daratumumab
Multiple myeloma · AL amyloidosis
BXT 2401
Emicizumab
Haemophilia A · Bleeding prevention
BXT 2408
Pembrolizumab
Multiple cancers · Immunotherapy
BXT 2409
Nivolumab
Advanced cancers · Immunotherapy
Team
Experience across
biologics development.
Gerrit Hagens
CEO & Board Member | PhD, MBA
Luc-Alain Savoy
Chairman of the Board | PhD
Cori Gorman
Board Member | PhD, MBA
